|
|
||||||||
Clinical Studies |
Department of Chemical Endocrinology, University Hospital Nijmengen, Nijmegen, The Netherlands.
OBJECTIVE: A novel assay was employed to study the free 1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations in various populations with different levels of 1,25(OH)2D and vitamin D binding protein (DBP). DESIGN: In 12 healthy women before and after 3 months of oral estrogen/progestagen treatment, 10 pregnant women, and 16 patients with a nephrotic syndrome and normal renal function, the concentrations of total and free 1,25(OH)2D, DBP and albumin were assessed. METHODS: The total concentration of 1,25(OH)2D in serum was assessed using a radioreceptor assay. The free fraction of 1,25(OH)2D was measured using symmetric dialysis. DBP was assessed using single radial immunodiffusion. Serum albumin concentrations were measured on an automated analyzer. RESULTS: In healthy women, the concentrations of total 1,25(OH)2D, free 1,25(OH)2D and DBP were 132+/-19 pmol/l, 92+/-30 fmol/l and 5.59+/-0.43 micromol/l. After 3 months of estrogen/progestagen treatment, total 1,25(OH)2D and DBP levels rose significantly to 175+/-51 pmol/l and 8.32+/-1.59 micromol/l (P< or =0.05 and P< or =0.001); the free 1,25(OH)2D remained unchanged (105+/-39 fmol/l; not significant). Pregnant women had significantly higher levels of total 1,25(OH)2D and DBP (239+/-68 pmol/l and 11.32+/-1.77 micromol/l; both P=0.001); the free 1,25(OH)2D level, however, was not different (104+/-27 fmol/l; not significant). Unexpectedly, in patients with nephrotic syndrome, no lower DBP levels were found (5.36+/-0.84 micromol/l) relative to that in controls. Despite this, levels of both total (69+/-26 pmol/l, P< or =0.001) and free 1,25(OH)2D (53+/-28 fmol/l; P< or =0.001) were significantly lower than in controls. Albumin levels were lowered from 628+/-38 micromol/l to 300+/-84 micromol/l (P < or = 0.001). CONCLUSIONS: Higher estrogen levels result in higher DBP levels, with a parallel rise in total 1,25(OH)2D levels but without a change in the biologically active free fraction. The results in patients with nephrotic syndrome show that, with increasing glomerular protein leakage, the free 1,25(OH)2D concentration cannot be maintained.
This article has been cited by other articles:
![]() |
A. Prentice, G. R Goldberg, and I. Schoenmakers Vitamin D across the lifecycle: physiology and biomarkers Am. J. Clinical Nutrition, August 1, 2008; 88(2): 500S - 506S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Zella, N. K. Shevde, B. W. Hollis, N. E. Cooke, and J. W. Pike Vitamin D-Binding Protein Influences Total Circulating Levels of 1,25-Dihydroxyvitamin D3 but Does Not Directly Modulate the Bioactive Levels of the Hormone in Vivo Endocrinology, July 1, 2008; 149(7): 3656 - 3667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Abbas, J. Linseisen, T. Slanger, S. Kropp, E. J. Mutschelknauss, D. Flesch-Janys, and J. Chang-Claude Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study Carcinogenesis, January 1, 2008; 29(1): 93 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Lauridsen, M. Aarup, A. L. Christensen, B. Jespersen, K. Brixen, and E. Nexo Sensitive Automated ELISA for Measurement of Vitamin D-Binding Protein (Gc) in Human Urine Clin. Chem., June 1, 2005; 51(6): 1016 - 1018. [Full Text] [PDF] |
||||
![]() |
U. Peters, R. B. Hayes, N. Chatterjee, W. Shao, R. E. Schoen, P. Pinsky, B. W. Hollis, K. A. McGlynn, and the Prostate, Lung, Colorectal and Ovarian Cancer Circulating Vitamin D Metabolites, Polymorphism in Vitamin D Receptor, and Colorectal Adenoma Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 546 - 552. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |